Meta AnalysisID 1512
β-丙氨酸、肌酸、咖啡因和辅酶Q10用于治疗神经退行性疾病的证据是什么？
CRD42022363638
Does beta alanine, creatine and coenzyme Q10 supplementation have a potential neuroprotective action in neurodegenerative diseases (Alzheimer's, Multiple Sclerosis, Amyotrophic Sclerosis, Huntington's and Parkinson's)?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1512
- Evidence Id
- 10070
- Core Evidence Id
- 10070
- Source Meta Analysis Id
- 1467
- Herb2 Meta Analysis Id
- HBMA001467
- Crd Id
- CRD42022363638
- Title
- What is the evidence of the use of beta alanine, creatine, caffeine and coenzyme Q10 in the treatment of neurodegenerative diseases?
- Review Question
- Does beta alanine, creatine and coenzyme Q10 supplementation have a potential neuroprotective action in neurodegenerative diseases (Alzheimer's, Multiple Sclerosis, Amyotrophic Sclerosis, Huntington's and Parkinson's)?
- Study Type Included
- The inclusion criteria will be the following: (1) the articles will be considered without any language restrictions; (2) studies including participants with the aforementioned neurodegenerative diseases, regardless of age; (3) if data subsets are published in more than one article, only the most recent subset will be included and (4) parallel randomized controlled trials (RCTs) and large prospective cohorts with control groups. The following studies will be excluded: (1) case reports; (2) publications that do not specifically report neurodegenerative diseases and (3) those with insufficient data to extract or calculated from the original article do not specifically report neurodegenerative diseases and (3) those with insufficient data to extract or calculated from the original article
- Condition Being Studied
- Clinical results, Biological (biochemical and immunological analyses) and behavioral measures that are directly related to the pathologies. Clinical outcomes, including scoring by validated questionnaires will be included.
- Participant
- Patients with Neurodegenerative Diseases (Alzheimer's, Multiple Sclerosis, Amyotrophic Sclerosis, Huntington's and Parkinson's) using beta alanine, creatine, caffeine and Coenzyme Q10, regardless of sex and age, will be included. Test analysis based on in other pathological conditions, even using the aforementioned nutraceuticals, they will be excluded.
- Animal
- Human Disease Modelled
- Intervention
- Randomized controlled trials and cohort studies with patients with neurodegenerative diseases (Alzheimer's, Multiple Sclerosis, Amyotrophic Sclerosis, Huntington's and Parkinson's) comparing beta alanine, creatine, caffeine and coenzyme Q10 supplementation interventions with a control or placebo group will be eligible. Studies comparing these therapies with another active intervention will be excluded.
- Comparator Control
- Parallel RCTs and cohort studies comparing beta alanine, creatine, caffeine and coenzyme Q10 supplementation interventions with concomitant control group that received no treatment or a placebo will be eligible. Studies comparing these therapies with another active intervention will be excluded.
- Main Outcome
- The effects of the intervention with the supplementation of beta alanine, creatine, caffeine and coenzyme Q10) in the described neurodegenerative diseases and the results of the evaluated clinical parameters.
- Outcome Measure
- Additional Outcome
- Biochemical and immunological markers that are used to assess the possible neuroprotective action of the nutraceuticals under study
- Study Method
- Epidemiologic, Intervention, Meta-analysis, Systematic review
- Keyword
- Alzheimer Disease; Caffeine; Creatine; Dietary Supplements; Humans; Multiple Sclerosis; Neurodegenerative Diseases; Parkinson Disease; Sclerosis; beta-Alanine; coenzyme Q10
- Contact
- ANTONIO CARLOS QUEIROZ DE AQUINO [email protected]
- Organisational Affiliation
- FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE
- Funding Source
- No funding sources
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Brazil
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-09-29
- Registration Date
- 2022-10-10
- Anticipated Start Date
- 2022-10-28
- Anticipated Completion Date
- 2023-04-28
- Title Cn
- β-丙氨酸、肌酸、咖啡因和辅酶Q10用于治疗神经退行性疾病的证据是什么？
- Title En
- What is the evidence of the use of beta alanine, creatine, caffeine and coenzyme Q10 in the treatment of neurodegenerative diseases?
- Bilingual Status
- complete